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Abstract
Malignant mesothelioma is a rare cancer that arises from the mesothelial cells that line the pleural 
cavity and less commonly from the peritoneal lining of the abdomen and pelvis. Most pleural 
mesotheliomas arise in patients with a history of asbestos exposure, whereas the association of 
peritoneal mesotheliomas with exposure to asbestos and other potential carcinogens is less clear, 
suggesting that the genetic alterations which drive malignant peritoneal mesothelioma may be 
unique from those in pleural mesothelioma. Treatment options for all malignant mesotheliomas are 
currently limited, with no known targeted therapies available. To better understand the molecular 
pathogenesis of malignant peritoneal mesothelioma, we sequenced 510 cancer-related genes in 13 
patients with malignant mesothelioma arising in the peritoneal cavity. The most frequent genetic 
alteration was biallelic inactivation of the BAP1 gene, which occurred in 9/13 cases, with an 
additional 2 cases demonstrating monoallelic loss of BAP1. All 11 of these cases demonstrated 
loss of BAP1 nuclear staining by immunohistochemistry, whereas the 2 tumors without BAP1 
alteration and all 42 cases of histologic mimics in peritoneum (8 multilocular peritoneal inclusion 
cyst, 6 well-differentiated papillary mesothelioma of the peritoneum, 16 adenomatoid tumor, and 
12 low-grade serous carcinoma of the ovary) demonstrated intact BAP1 nuclear staining. 
Additional recurrently mutated genes in this cohort of malignant peritoneal mesotheliomas 
included NF2 (3/13), SETD2 (2/13), and DDX3X (2/13). While these genes are known to be 
recurrently mutated in pleural mesotheliomas, the frequencies are distinct in peritoneal 
mesotheliomas, with nearly 85% of peritoneal tumors harboring BAP1 alterations versus only 
20-30% of pleural tumors. Together, these findings demonstrate the importance of epigenetic 
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modifiers including BAP1, SETD2, and DDX3X in mesothelial tumorigenesis and suggest 
opportunities for targeted therapies.
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Malignant peritoneal mesothelioma; well-differentiated papillary mesothelioma; benign 
multicystic mesothelioma; adenomatoid tumor; low-grade serous carcinoma; BAP1; NF2; SETD2; 
DDX3X
INTRODUCTION
Malignant mesothelioma is a rare cancer that arises from the mesothelial cells that line the 
pleural cavity (>80% of cases) and less commonly from the peritoneal lining of the 
abdominal and pelvic cavities (10-15%), the pericardial lining, and the tunica vaginalis. 
Approximately 2,500 malignant mesotheliomas are newly diagnosed in the United States 
each year, which have a uniformly poor prognosis and median survival time of less than two 
years. Greater than 80% of malignant pleural mesotheliomas arise in patients with a history 
of asbestos exposure, whereas malignant peritoneal mesotheliomas have less clear risk 
factors that include chronic peritonitis.1 Patients with malignant peritoneal mesothelioma are 
more commonly female, of younger age, and have better prognosis than patients with pleural 
mesothelioma, though most patients will eventually die of disease.2
Genomic analysis has defined the spectrum of molecular alterations that drive pleural 
mesothelioma. These include deletion of the CDKN2A tumor suppressor gene (>60% of 
cases) that encodes the cell cycle kinase inhibitor protein p16INK4a, mutation of the NF2 
tumor suppressor gene (20-40% of cases) that encodes the cytoskeletal scaffolding protein 
Merlin, and mutation or deletion of the BAP1 tumor suppressor gene (20-30% of cases) that 
encodes a deubiquitinating enzyme originally identified as a BRCA1 interacting protein.3-7. 
Most recently, four distinct molecular subtypes were identified that correlated with 
epithelioid, sarcomatoid, biphasic-epithelioid, and biphasic-sarcomatoid histologies, with the 
epithelioid subtype showing the longest survival times. 7 Inactivating mutations in two 
epigenetic regulatory genes, DDX3X and SETD2, were identified in a 4% and 8% of pleural 
mesotheliomas, respectively.7 In addition to these somatic mutations found in sporadic 
mesotheliomas, germline mutation of BAP1 has been identified in rare patients with 
malignant mesothelioma as part of the BAP1 tumor predisposition syndrome (OMIM 
603089), which in addition to mesothelioma includes increased incidence of uveal 
melanoma, meningioma, renal cell carcinoma, and other tumors.8-9 Given the frequent 
genetic inactivation of CDKN2A and BAP1 in malignant pleural mesothelioma, several 
recent studies have assessed the sensitivity and specificity of either fluorescence in situ 
hybridization (FISH) or imunohistochemistry against these two genes/proteins as helpful 
diagnostic markers to distinguish malignant mesothelioma from benign mesothelial 
proliferations and metastatic carcinoma in pleural fluid.10-14 BAP1 immunostaining has 
clearly emerged as a useful adjunct for the cytopathologist in characterizing mesothelial 
proliferations in the pleural cavity.
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The genetic alterations which drive malignant mesothelioma in the peritoneum and other 
body cavities have been speculated to potentially be distinct from pleural mesotheliomas but 
had not been investigated until very recently. Indeed, one study performed FISH on 
mesotheliomas from different sites of origin and found chromosome 9p21 deletion much 
more commonly in pleural than peritoneal tumors (85% versus 36%), whereas 5p15 and 
7p12 gains were more common in peritoneal than pleural tumors.15 A recent genome-wide 
analysis of 12 peritoneal mesotheliomas found BAP1 alterations (either deletions or 
truncating mutations) in 7 cases, but failed to identify alterations in CDKN2A or NF2 that 
are common in pleural mesotheliomas.16 Another recent study correlating genetic status 
with outcomes for patients with peritoneal mesothelioma identified frequent loss of BAP1 
immunostaining that did not correlate with significant differences in outcome, but did find 
that tumors harboring both CDKN2A homozygous deletion and NF2 hemizygous loss were 
associated with worse progression-free and overall survival.17 The specificity of BAP1 loss 
in mesothelial proliferations and histologic mimics of malignant mesothelioma in the 
peritoneum including serous carcinoma of the ovary is currently under investigation and has 
shown promising results in the limited investigations performed to date.12,13,18
Given their uniformly poor prognosis, lack of well-established risk factors, and poorly 
understood pathogenesis, we sought to better define the genetic events that define malignant 
peritoneal mesothelioma and potentially identify targetable alterations to ultimately improve 
outcomes through a combination of next generation sequencing and immunohistochemical 
assays.
MATERIALS AND METHODS
Study population
This study was approved by the Institutional Review Board of the University of California, 
San Francisco. Thirteen cases of primary malignant peritoneal mesotheliomas were retrieved 
from the archives of the University of California, San Francisco Department of Pathology, 
spanning years 1991 to 2015. All thirteen cases were confined to the abdomen and pelvis 
and had no evidence of pleural involvement. All cases were re-reviewed by three 
gynecologic pathologists who agreed with the diagnosis of malignant mesothelioma. All 13 
cases demonstrated epithelioid morphology, while one case also had a focal sarcomatoid 
component. Cases of multilocular peritoneal inclusion cyst also known as benign multicystic 
mesothelioma (n=8), well-differentiated papillary mesothelioma of the peritoneum (n=6), 
adenomatoid tumor (n=16), and low-grade serous carcinoma of the ovary (n=12) were also 
retrieved from the archives of the University of California, San Francisco Department of 
Pathology, spanning years 2000-2015. All specimens were fixed in 10% neutral buffered 
formalin and embedded in paraffin. Clinical information on patients with malignant 
peritoneal mesothelioma was obtained from electronic medical records. Selected histologic 
and clinicopathologic parameters were recorded, including patient age at diagnosis, location 
of tumor, type of surgical procedure, treatment, and outcome.
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Capture-based Next Generation DNA Sequencing (NGS)
Genomic DNA was extracted from formalin-fixed paraffin-embedded tissue blocks of 
matched normal and tumor tissues of 13 patients with malignant peritoneal mesothelioma 
using the QIAamp DNA FFPE Tissue Kit (Qiagen). Capture-based NGS was performed at 
the University of California, San Francisco Clinical Cancer Genomics Laboratory, using an 
assay that targets the coding regions of 510 cancer-related genes, select introns of 40 genes, 
and TERT promoter with a total sequencing footprint of 2.8 Mb (UCSF500 Cancer Gene 
Panel). Sequencing libraries were prepared from genomic DNA. Target enrichment was 
performed by hybrid capture using a custom oligonucleotide library. Sequencing was 
performed on an Illumina HiSeq 2500. Duplicate sequencing reads were removed 
computationally to allow for accurate allele frequency determination and copy number 
calling. The analysis was based on the human reference sequence (NCBI build 37) using the 
following software packages: BWA, Samtools, Picard tools, GATK, CNVkit, Pindel, SATK, 
Annovar, Freebayes, Delly, and Nexus Copy Number.19-26
Immunohistochemistry
Immunohistochemistry for BAP1 was performed on whole tissue sections of cases of 
malignant peritoneal mesothelioma (n=14), well-differentiated papillary mesothelioma of 
the peritoneum (n=6), multilocular peritoneal inclusion cyst (n=8), adenomatoid tumor 
(n=16), and low-grade serous carcinoma of the ovary (n=12). A monoclonal BAP1 antibody 
(clone C-4, Santa Cruz Biotechnology, sc-28383) was used at 1:100 dilution following ER2 
antigen retrieval on a Leica Bond autostainer. BAP1 staining was scored as either intact 
(strong homogeneous nuclear staining of >90% of tumor cells) or lost (no nuclear staining in 
tumor cells with intact expression in non-neoplastic stromal and endothelial cells).
RESULTS
Histologic and clinical features of malignant peritoneal mesotheliomas
Thirteen cases of malignant mesothelioma confined to the abdomen and pelvis without 
pleural involvement were retrieved from our institutional pathology archives. These included 
8 female patients (ages 19-89) and 5 male patients (ages 53-71). Twelve of the 13 cases 
demonstrated a predominantly epithelioid morphology, while one case had mixed epithelioid 
and sarcomatoid morphology. Limited clinical outcome data was available for the 13 cases, 
which is summarized in Table 1.
Genomic alterations in malignant peritoneal mesotheliomas
Targeted next-generation sequencing of 510 cancer-associated genes revealed pathogenic 
genetic alterations in each of the 13 cases (Figure 1, Supplemental Table 1). BAP1 
alterations were identified in 11 of 13 tumors (85%). Of these 11 cases, three had somatic 
BAP1 mutations accompanied by loss of heterozygosity (one with a frameshift mutation, 
p.D362fs; one with a splice site mutation, c.68-1G>A; and one with a missense mutation, 
p.L97Q). One case had two somatic BAP1 mutations (p.H669D and p.86_87del). 
Additionally, two cases had focal homozygous deletions of the BAP1 locus, and two cases 
had structural rearrangements involving BAP1 accompanied by loss of heterozygosity. Two 
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cases demonstrated heterozygous loss of the BAP1 locus on chromosome 3p but lacked an 
identifiable alteration of the second allele. The final case had a germline frameshift mutation 
in BAP1 (p.L573fs) that was accompanied by loss of heterozygosity in the tumor. Of the 9 
cases with biallelic BAP1 alterations, two cases also demonstrated inactivating frameshift 
mutations (p.V2345fs and p.Q1152fs) in the epigenetic regulatory gene SETD2 with 
accompanying loss of heterozygosity. One of these tumors also harbored a truncating 
mutation (p.L1051fs) in the ARID1A gene, which encodes a subunit of the Swi/Snf 
chromatin remodeling complex. In addition, two other cases with biallelic BAP1 alteration 
demonstrated mutations in another epigenetic regulatory gene, DDX3X. Three tumors 
harbored inactivating mutations in the NF2 tumor suppressor gene (p.Q428*, p.F47fs, and 
p.L176fs) including both of the two cases with heterozygous BAP1 loss and one case 
without BAP1 alteration or chromosome 3p loss. These three truncating mutations in NF2 
were each accompanied by loss of heterozygosity. In the remaining case without BAP1 or 
NF2 alteration, a hotspot mutation in the TERT promoter (chr5: g.1,295,228G>A) was the 
solitary pathogenic alteration identified. The two tumors without BAP1 alteration occurred 
in the oldest (age 85) and youngest (age 19) patients in this cohort and each demonstrated a 
solitary genetic alteration, NF2 truncating mutation with loss of heterozygosity in the 85 
year old and TERT promoter mutation in the 19 year old. The one case of peritoneal 
mesothelioma with mixed epithelioid and sarcomatoid morphology was the only case found 
to harbor homozygous deletion of CDKN2A and focal high-level amplification of the MET 
oncogene in addition to a structural rearrangement involving BAP1.
BAP1 immunohistochemistry can aid in the diagnosis of malignant peritoneal 
mesothelioma
BAP1 immunohistochemistry was performed on all 13 malignant peritoneal mesotheliomas 
(Figure 2, Table 2), as well as a series of tumors commonly considered in the differential 
diagnosis of malignant peritoneal mesothelioma including 6 cases of well-differentiated 
papillary mesothelioma, 8 cases of multicystic peritoneal inclusion cyst, 16 cases of 
adenomatoid tumor, and 12 cases of low-grade serous carcinoma of the ovary (Figure 3, 
Table 2). Loss of nuclear staining for BAP1 protein was seen in 11 of the 13 peritoneal 
mesotheliomas (85%), all of which demonstrated genetic alteration of the BAP1 gene. In all 
11 of these tumors, retained BAP1 expression was present in non-neoplastic stromal, 
inflammatory, and endothelial cells. Moreover, BAP1 loss was seen uniformly throughout all 
tumor cells in each case, suggesting that BAP1 inactivation is an early or initiating event in 
mesothelial tumorigenesis. The absence of nuclear BAP1 protein in the two tumors with 
only heterozygous loss of the BAP1 locus suggests a high likelihood of an unidentified 
alteration involving the second allele and potentially indicates that BAP1 
immunohistochemistry may be a more sensitive diagnostic test for BAP1 inactivation 
compared to capture-based next-generation sequencing assay. Intact nuclear staining for 
BAP1 protein was present in 2 of the 13 peritoneal mesotheliomas, both of which 
demonstrated two wild-type copies of BAP1 by our sequencing assay. All 42 cases of well-
differentiated papillary mesothelioma of the peritoneum, multilocular peritoneal inclusion 
cyst, adenomatoid tumor, and low-grade serous carcinoma of the ovary demonstrated intact 
BAP1 nuclear staining.
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DISCUSSION
Our study reveals that while a similar spectrum of genetic alterations define both pleural and 
peritoneal mesothelioma, these alterations occur at distinct frequencies depending on the 
anatomic origin of the tumor. While CDKN2A deletion is very common in pleural 
mesotheliomas, it was only seen in one of 13 peritoneal mesotheliomas, which was the only 
case with a sarcomatoid component. In contrast, BAP1 inactivation/loss is much more 
common in peritoneal than pleural mesotheliomas. DDX3X and SETD2 mutations appear to 
be present in a small subset (5-15%) of both pleural and peritoneal mesotheliomas. A recent 
array comparative genomic hybridization study on 33 malignant peritoneal mesotheliomas 
identified focal deletions affecting BAP1 (61% of cases), NF2 (21% of cases), and 
CDKN2A (33% of cases), providing additional support for our conclusion that similar 
genetic alterations drive peritoneal mesothelioma but at different frequency compared to 
pleural mesothelioma.27
Our study also provides further support for the specificity of BAP1 protein loss as a helpful 
diagnostic marker for the pathologic identification of malignant peritoneal 
mesotheliomas.10-14 We observed intact BAP1 expression in all 42 cases of potential 
histologic mimics in the abdomen and pelvis including well-differentiated papillary 
mesothelioma, multilocular peritoneal inclusion cyst, adenomatoid tumor, and peritoneal 
metastases of ovarian low-grade serous carcinoma.
Finally, our genomic profiling of malignant peritoneal mesothelioma has identified recurrent 
mutations in the epigenetic regulatory genes BAP1, SETD2, and DDX3X. These findings 
suggest that transcriptional deregulation is a key oncogenic mechanism in mesothelial 
tumorigenesis and has important therapeutic implications for the treatment of this disease. 
Emerging preclinical evidence suggests that inhibitors of epigenetic modifiers including 
histone deacetylases and the histone methyltransferase EZH2 may be efficacious in the 
treatment of mesothelioma.28-29 Those mesotheliomas harboring inactivating events 
affecting both BAP1 and other transcriptional regulators such as SETD2, DDX3X, and 
ARID1A likely define a molecular subgroup with altered transcriptional programs that may 
respond favorably to these agents, compared to those mesotheliomas lacking these 
alterations. Additional potentially targetable alterations that emerged from our study include 
small molecule inhibition of MET (e.g. cabozantinib) for the subset of peritoneal 
mesotheliomas harboring MET amplification, as well as small molecule inhibition of WEE1 
(e.g. AZD1775) for the subset of tumors harboring SETD2 inactivation, a synthetic lethality 
that was recently reported in renal cell carcinoma and osteosarcoma.30
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Figure 1. 
Genomic profiling results on 13 patients with malignant peritoneal mesothelioma. Patient 
age, sex, tumor histologic subtype, chromosome 3p status, BAP1 nuclear immunostaining 
results, pathogenic or likely pathogenic genetic alterations, and the quantity of chromosomal 
copy number aberrations are shown.
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Figure 2. 
Loss of nuclear BAP1 expression defines the majority of malignant peritoneal 
mesotheliomas arising within the abdomen and pelvis. (A-C) Absence of BAP1 
immunostaining in a malignant mesothelioma arising in the abdomen/pelvis of a 70 year old 
woman (patient MPM11) with interstitial deletion of chromosome 3p encompassing the 
BAP1 locus, as well as an NF2 frameshift mutation. Retained BAP1 expression is seen in 
non-neoplastic stromal, inflammatory, and endothelial cells. (D-F) Absence of BAP1 
immunostaining in a malignant mesothelioma arising in the abdomen/pelvis of a 67 year old 
man (patient MPM7) with focal homozygous deletion of a 300 kb segment on chromosome 
3p encompassing the BAP1 locus. (G-I) Intact BAP1 immunostaining in a malignant 
mesothelioma arising in the abdomen/pelvis of a 19 year old woman (patient MPM13) with 
hotspot mutation in the TERT promoter, without chromosome 3p loss or BAP1 alteration.
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Figure 3. 
Intact BAP1 expression is uniformly present in benign mesothelial lesions and other 
histologic mimics of malignant mesothelioma in the peritoneum. (A-C) Intact BAP1 
immunostaining in a well-differentiated papillary mesothelioma within the abdomen of a 67 
year old woman who presented with gastric volvulus and was found to have peritoneal 
nodularity along the stomach and liver. (D-F) Intact BAP1 immunostaining in an 8 cm 
multilocular peritoneal inclusion cyst in the pelvic cavity of a 62 year old woman. (G-I) 
Intact BAP1 immunostaining in a 2 cm paratesticular adenomatoid tumor in a 43 year old 
man who underwent orchiectomy. (J-L) Intact BAP1 immunostaining in an ovarian low-
grade serous carcinoma in an 83 year old woman with multiple metastatic deposits 
throughout the abdomen and pelvis.
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Table 1
Clinical data for patients with malignant peritoneal mesothelioma.
Patient Age at dx Sex Year of dx Presenting symptoms Clinical outcome data
MPM1 74 F 2009 abdominal distention
diagnosed on paracentesis followed by hysterctomy/bilateral 
salpingo-oophorectomy/omentectomy/debulking, no follow-up
available after surgery
MPM2 89 F 2008 bowel obstruction diagnosed on bilateral oophorectomy/myomectomy/mesenteric biopsy, no follow-up available after surgery
MPM3 48 F 1996 pelvic pain
initially underwent hysterectomy/bilateral salpingo-oophorectomy 
with atypical mesothelial proliferation, 7 months later
underwent diagnostic surgical resection of 10 cm pelvic mass and left 
colectomy, received intraperitoneal chemotherapy with
cisplatin/doxorubicin/taxol, underewent radiation therapy, underwent 
two additional debulking surgeries at one and two after
diagnosis, presented with bowel obstruction at three years after 
diagnosis due to recurrent disease, referred to hospice care
without additional treatment
MPM4 47 F 2008 vaginal bleeding
diagnosed on hysterectomy/bilateral salpingo-oophorectomy/
omentectomy/debulking, metastatic disease to cervical lymph
nodes confirmed by biopsy at time of diagnosis, received 8 cycles of 
adjuvant chemotherapy with pemetrexed and cisplatin,
imaging showing recurrent disease at one year after surgery, began 
additional treatment with gemcitabine and vinorelbine,
no additional follow-up available
MPM5 48 M 1993 umbilical hernia
diagnosed on herniorrhaphy followed by debulking surgery, received 
adjuvant intraperitoneal chemotherapy, underwent
repeat debulking surgeries at two and five years after diagnosis, no 
additional follow-up available after last debulking surgery
MPM6 54 M 2004 abdominal distention
diagnosed on paracentesis, received 6 cycles of neoadjuvant 
chemotherapy with pemetrexed and cisplatin, then underwent
debulking surgery with right colectomy, no follow-up available after 
surgery
MPM7 67 M 1991 abdominal wall mass diagnosed on resection of mass and involved small bowel, no follow-
up available after surgery
MPM8 55 M 2000 abdominal distention
and ascites
initially had five non-diagnostic paracentesis cytologic evaluations, 
diagnosed on laparoscopy with omental biopsy followed by
omentectomy and surgical debulking, no follow-up available after 
surgery
MPM9 62 F 2014 pelvic mass diagnosed on hysterectomy/bilateral salpingo-oophorectomy/
omentectomy/colectomy, no follow-up available after surgery
MPM10 71 M 2002 abdominal distention diagnosed on omentectomy and debulking surgery, no follow-up 
available after surgery
MPM11 70 F 2014 abdominal distention
and ascites
diagnosed on laparoscopy with omental biopsy, no follow-up 
available after biopsy
MPM12 85 F 2006 abdominal distention
and ascites
diagnosed on hysterectomy/bilateral salpingo-oophorectomy/omental 
biopsy, no follow-up available after surgery
MPM13 19 F 2004 abdominal distention
diagnosed on bilateral salpingo-oophorectomy/omentectomy/surgical 
debulking, received adjuvant chemotherapy with 4
cycles of pemetrexed and cisplatin, developed recurrent disease four 
years after diagnosis, received 3 cycles of pemetrexed
and carboplatin, underwent hysterectomy and surgical debulking, 
treated with gemcitabine then vinorelbine then liposomal
doxorubicin, died of disease six years after diagnosis
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Table 2
BAP1 immunostaining results on malignant peritoneal mesotheliomas and histologic mimics in the 
peritoneum.
Tumor type
Cases with loss of
nuclear BAP1
immunostaining
Total number
of cases
% with
BAP1 loss
Malignant peritoneal mesothelioma 11 13 85%
Ovarian low grade serous carcinoma 0 12 0%
Well-differentiated papillary mesothelioma 0 6 0%
Multilocular peritoneal inclusion cyst 0 8 0%
Adenomatoid tumor 0 16 0%
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